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Abstract
Background: This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis
obliterans (Buerger’s disease) patients.
Methods: A clinical pilot study was designed in which patients with ulcer and/or pain at rest were treated with
bosentan p.o. at a dose of 62.5 mg twice daily during the first month, which was thereafter up-titrated to 125 mg
twice daily. The study endpoints were clinical improvement rate, major or minor amputation rate, haemodynamic
changes, changes in endothelial function and angiographic changes.
Results: Seven out of 12 patients were male (58%). Median age was 39 years (range 29-49). The median follow-up
was 20 months (range 11-40). All patients were smokers. With bosentan treatment, new ischaemic lesions were
observed in only one patient. Overall, clinical improvement was observed in 12 of the 13 extremities (92%). Only
two out of 13 extremities underwent amputation (one major and one minor) after bosentan treatment. After being
assessed by digital arteriography with subtraction or angio-magnetic resonance imaging, an increase of distal flow
was observed in 10 out of the 12 patients. All patients experienced a statistically significant improvement in their
BAFMD values (mean: 1.8 at baseline; 6.6 at the end of the treatment; 12.7 three months after the end of the
treatment; p < 0.01).
Conclusion: Bosentan treatment may result in an improvement of clinical, angiographic and endothelial function
outcomes. Bosentan should be investigated further in the management of TAO patients. Larger studies are
required to confirm these results.
Trial Registration: ClinicalTrials.gov: NCT01447550
Background
Buerger’s disease, also known as thromboangiitis obliter-
ans (TAO), is a thrombotic, occlusive, non-atherosclero-
tic, segmental vasculitis of small and medium-sized
arteries and veins, which may involve both upper and
lower extremities. The onset usually occurs in people of
around the age of 45, and is more frequent in male
smokers. As a consequence of the increase in tobacco
use, an increase in the incidence of TAO in women has
been observed in the last 20 years [1,2].
Intermittent claudication and, in more advanced cases,
pain at rest are the predominant clinical symptoms. Dis-
tal ischaemic lesions (trophic and ulcerations) are fre-
quently observed by means of physical examination.
Clinical course is characterised by alternating periods of
exacerbation with periods of remission. Angiographic
studies reveal a distal and segmental involvement of the
vasculature of the extremities. Recanalisation is fre-
quently demonstrated, showing a typical image (cork-
screw collateral vessels) [3]. Skin disorders such as
migrating phlebitis or Raynaud-like colour changes may
be associated with TAO.
Giving up smoking is the most important therapeutic
measure in TAO patients [4]. In fact, it leads to dra-
matic improvement of the symptoms and lesions.
Amongst the drugs used to manage TAO, prostacyclin
(PGI2) or its analogues (iloprost, beraprost, trepostinil
sodium), aspirin or streptokinase (as a thrombolytic) are
the most important. Revascularisation by means of a by-
pass surgery or endovascular procedure is usually not
possible as a consequence of the predominantly diffuse
and distal location of the lesions in the veins and
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any medium, provided the original work is properly cited.arteries involved. Endothelin-1 (ET-1) is a potent vaso-
constrictor peptide, which exerts its action by targeting
two transmembrane receptors (ETA and ETB). Pharma-
cologic ET-1 receptor blockade, may be single (ETA or
ETB) or dual (both, ETA and ETB) [5]. Bosentan is a
dual ET-1 receptor antagonist, administered orally,
which is approved in the European Union to treat pul-
monary arterial hypertension in systemic sclerosis
patients and to prevent the occurrence of new digital
ulcers in systemic sclerosis patients with ongoing digital
ulcers. The results of a small retrospective study [6-8]
and a prospective study [9] suggested that bosentan
could have a role in healing ongoing digital ulcers in
systemic sclerosis.
Based on these previously reported studies on digital
ulcers in Systemic Sclerosis patients, we designed a pilot
study in order to assess both the safety and effectiveness
of bosentan in the pharmacologic management of
ischaemic symptoms and ulcers in TAO patients, the
results of which are reported herein.
Methods
Patients
In order to be included in the study, the patients had
to have a previous diagnosis of TAO, fulfilling the
Shionoya criteria [10]: 1) onset of distal ischaemic
symptoms in one extremity before the age of 50 years,
2) smoker or history of smoking, 3) distal ischaemia of
the extremity confirmed by a non-invasive test (ankle-
brachial index [ABI], toe-brachial index or partial pres-
sures), 4) absence of thrombophilia, autoimmune dis-
ease, diabetes, hyperlipidaemia, trauma or a proximal
source of underlying embolism, 5) arterial tree proxi-
mal to the distal segment of the healthy superficial
femoral artery, and 6) occlusive distal disease with spe-
cific elements or actual pathological findings demon-
strated angiographically or by means of angio-magnetic
resonance imaging. The consecutive patients included
in this study were required to meet the following
inclusion criteria: critical ischaemia in any extremity,
pain at rest or non-healing ischaemic ulcers, present
for at least four weeks with no evidence of improve-
ment in response to conventional treatment; not being
candidates for surgical or endovascular revascularisa-
tion of the extremity studied; objective confirmation of
the ischaemia in the affected extremity by means of an
A B Ia tr e s to fl e s st h a n0 . 6 ,i fi tw a st h el o w e re x t r e -
mity, or a partial pressure of less than 50 mmHg in
the upper extremity, in two consecutive assessments at
least one week apart. In each patient included with
pathological conditions in the upper extremities was
performed a study to assess blood flow in the upper
limb affection performing an Allen test, the determina-
tion of the Digital/Brachial Index (DBI), Radial/
Brachial Index (RBI) or Ulnar/Brachial Index (UBI)
and the determination of the partial pressure in the
radial artery. DBI, RBI and UBI indexes were defined
as the ratio of the segmental arterial pressures of the
digital arteries, radial and ulnar, respectively, and the
partial pressure in the brachial artery.
We considered a ratio < 0.7 in DBI, RBI and UBI as
an indicator of an inadequate blood perfusion in the
upper limb [11-13]. Conventional treatment includes:
advice for patients on giving up smoking; surgical or
endovascular revascularisation of the extremity when
possible, peripheral sympathectomy; prostanoid vasodi-
lator iloprost (in a 21-day cycle). The exclusion criteria
were as follows: any known contraindication for treat-
ment with bosentan such as patients with liver failure
or liver diseases, with anaemia or pregnant women;
presence of arteriosclerotic risk factors, apart from
smoking (hypertension, hyperlipidaemia and/or dia-
betes mellitus), any other medical or psychological
condition which may represent, in the investigator’s
opinion, a contraindication to either bosentan treat-
ment or to adequately performing the treatment and
procedures of the study. Patients with other causes or
forms of peripheral vasculopathy such as popliteal
entrapment syndrome, cystic adventitial disease, col-
lagenopathy and hypercoagulability (e.g. the presence
of Factor V Leiden or antiphospholipid syndrome)
were also excluded from the study.
Design
The study was designed as a pilot, open-label, non-con-
trolled, non-randomised, single centre clinical study,
where patients previously diagnosed with TAO received
treatment with bosentan in a compassionate use pro-
gramme. No concomitant medication was administered
during the study period except analgesics and
antibiotics.
The study protocol was approved by the Institutional
Review Board of the participating centre and regulatory
authorities. Patients were required to give written
informed consent before enrolment.
The study endpoints were clinical improvement rate
(absence of new trophic lesions, ulcer healing process,
pain relief, complete absence of pain), major or minor
amputation rate, haemodynamic changes as measured
by means of ABI, changes in endothelial function as
measured by means of the brachial artery flow-mediated
dilation test (BAFMD), and angiographic changes as
measured by an arteriography with digital subtraction or
angio-magnetic resonance imaging (MRI).
Clinical therapeutic success was defined as the com-
plete healing of the distal ischaemic trophic lesion or
complete ischaemic pain relief at rest if the patient pre-
sented no lesion.
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All included patients received a treatment regimen with
bosentan for compassionate use, after strict compliance
with the inclusion criteria and the absence of exclusion
criteria were ascertained. Bosentan therapy consisted of
am o n t h ’s treatment with 62.5 mg twice daily (bid)
administered orally. The initial dose was doubled to 125
mg bid after the first month if significant adverse events
attributable to bosentan were ruled out. This full-dose
regimen (125 mg/12 h) was maintained for the following
three months or until total healing of the ulcers, pro-
vided that the liver function tests and blood cell count
remained within the normal range. Patients were given
analgesic treatment, as necessary, to control pain at rest.
The ischaemic lesions and necrotic ulcers were treated
with standard daily care and antibiotherapy as necessary.
Special methods of treatment were not used and nor
was absolute bed rest prescribed during the study
period.
Patient assessments
All patients were monitored fortnightly on an outpatient
basis, at baseline, weekly for the first eight weeks after
the start of bosentan treatment, and monthly thereafter.
Baseline assessments included medical history, concomi-
tant medication requirements, (mainly analgesics or
antibiotics), and a complete physical examination.
Laboratory assessments, such as liver function tests and
blood cell counts were performed, as well as frequent
immunological tests.
In addition, a pregnancy test was performed in women
of childbearing age. The ischaemic ulcers were docu-
mented with colour photographs for all patients before
the BAFMD was assessed. The target extremity for
assessment purposes was defined as the one presenting
the trophic lesion or causing pain at rest.
Baseline haemodynamic studies included the ABI at
rest, and the partial brachial pressures (absolute value).
Bioactivity of bosentan was assessed by means of
BAFMD, as an indirect measurement of the endothelial
function that is based on the capacity of nitric oxide
(NO) production released by the endothelium, which
may lead to arterial dilation. This measurement is
achieved by means of an ultrasonography, a non-inva-
sive technique based on parietal stress, caused by
increased flow after a period of ischaemia. This causes
the opening of ionic channels, thereby increasing the
concentration of intracellular calcium and stimulating
the enzymatic activity of endothelial NO synthase. As a
result, there is a relaxation of smooth muscle, together
with dilation of the brachial artery [14].
Measurement of BAFMD: Before the test, all patients
fasted for a minimum of 12 hours and were advised not
t op a r t a k ei np h y s i c a le x e r c i s eo rs m o k e .T h e yw e r e
placed in dorsal decubitus, in a calm environment and
under controlled room temperature. A Doppler ultra-
sound machine (HD11 XE, PHILIPS, Eindhoven, The
Netherlands) was used with a L12-3-MHz linear probe.
After obtaining an image at rest, ischaemia was applied
at a pressure of 250 mmHg over a period of five min-
utes. Another image was obtained 60 seconds after
releasing ischaemia. The BAFMD was calculated as the
as the post-ischaemic diameter after 60 seconds, minus
the diameter at rest, divided by the diameter at rest and
expressed as a percentage.
BAFMD was assessed according to a previously
described technique [14], in each patient before and
after treatment with bosentan and three months after
the end of treatment. An arteriography with digital sub-
traction (or an angio-MRI) was performed at baseline
and three months after the last dose of bosentan.
During follow-up, all the information on the clinical
symptoms, evolution of trophic lesions, presence/
absence of major or minor amputation, smoking and
patient’s physical activity was collected. This information
was obtained directly from the guided anamnesis, physi-
cal examination and photographs that were taken at the
successive follow-up visits.
Outcome assessments and techniques
The criteria we used to document the changes in the
status of the target extremity were taken from the Inter-
Society Consensus for the Management of Peripheral
Arterial Disease (TASC II) consensus-based standard
recommendations [15]. The haemodynamic effect of
bosentan on macrocirculation was determined by means
of the ABI, which was obtained by taking the systolic
pressure figure in the posterior tibial artery at maleolar
level or the dorsalis pedis artery and dividing this mea-
surement by the brachial artery systolic pressure. These
measurements were always taken with the patient in the
s u p i n ep o s i t i o na n df o l l o w i n gar e s tp e r i o do f1 5m i n -
utes, using a continuous bidirectional Doppler ultra-
sound device. The drug’s bioactivity was shown through
the monitoring of the improvement in patient endothe-
lial function, produced by the treatment and indirectly
measured by means of BAFMD, as was previously
described.
Statistical analysis
Qualitative variables were described by frequencies and
percentages and quantitative variables by mean ± stan-
dard error or median and range. Differences between
time points were compared, using the Wilcoxon test for
dependent samples and the Friedman test for repeated
measurements. The threshold of statistical significance
was established as p < 0.05. Statistical analyses were per-
formed using SSPS version 16.0.
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Patients
A total of 12 consecutive patients were included in the
study (58% men). One patient had both an ulcer on one
foot and ulcers on their fingers. As a consequence,
results refer to 12 patients and 13 extremities. The med-
ian follow-up was 20 months (range 11-40). Table 1
shows the demographic and clinical data of the patients
as well as BAFMD results. Prior to the treatment with
bosentan, three extremities in three different patients
(25%) had undergone revascularising procedures and
three patients (25%) had a lumbar sympathectomy. Ten
out of 12 patients (83%) had previously been treated
with a 21-day prostaglandin regimen. In all these pre-
treated patients, bosentan treatment began after a mini-
mum period of 15 days with no clinical improvement in
the symptoms or healing of the ischaemic ulcers. Eleven
patients with trophic lesions in one or more finger(s) or
toe(s) were included. One patient presented lesions on
the back of the foot at baseline. Only one patient pre-
sented ischaemic pain at rest with skin integrity at base-
line. The upper extremity was involved in three patients,
in the form of ulcerous lesions in the pads of the fingers
or periungual areas.
Seven patients were male (58%). The median age of
the patients was 39 years (range 29-49). Seven patients
(58%) had previously been diagnosed with at least one
episode of phlebitis migrans. All patients were current
smokers and had been heavy smokers for years. Eight
patients (67%) were unable to completely abstain from
smoking during the follow-up.
We discarded the presence of associated autoimmune
diseases in patients due to all the immunological testing
included, as tests for C-reactive protein, rheumatoid fac-
tor, antinuclear antibodies, anti-DNA antibodies, antiri-
bonucleoprotein antibodies, anti-Ro antibodies, anti-Sm
antibodies, anti-Jo-1 antibodies and antineutrophil cyto-
plasmic antibodies were negative. Levels of complement
C3 and C4, and thyroid stimulating hormone, were nor-
mal in all patients. Tests for anticardiolipin antibodies
were negative, as were tests for syphilis, HIV, and hepati-
tis B and C. Diagnoses of cardiogenic or aortic embolism,
early-onset occlusive atherosclerotic disease, collagen dis-
ease and hypercoagulable state were excluded.
As shown by angiography, the infrapopliteal arteries
were involved in the 10 patients with lesions on the
lower extremities, whereas the upper extremities were
involved in three patients (25%). Either a digital arterio-
graphy with subtraction or an angio-MRI documented
the typical findings of Buerger’s disease in all 12 patients
at baseline. These findings included segmental occlusive
disease, mainly affecting the tibial, forearm and digit
vessels, as well as the plantar and palmar arches,
although this involvement extended proximally to the
popliteal artery in two cases. In all cases the typical
corkscrew collateral vessels were observed and the prox-
imal vessels to the superficial femoral artery were free of
any sign of disease.
Table 1 Patient characteristics and results of brachial artery flow-mediated dilation test
No. Age Gender Prior
treatment
Give up
smoking
Months
F/u
Pre-treatment
clinical results
Post-treatment
clinical results
BAFMD Pre-
treatment
BAFMD Post-
treatment
BAFMD 3
months after
1 35 F PG + LS YES 20 Ulcer in toe Healing 1.1 6.7 11.6
2 36 F PG YES 40 Ulcer in toes Healing 0 5.2 17.1
3 32 M PG NO 21 Ulcer in fingers Healing 1.5 6.9 10.8
4 46 F PG NO 20 Ulcer in fingers Healing 0.8 6.5 12.3
5 47 M PG NO 12 Pain at rest Pain relief
Claudicates 300 m
2.3 7.1 12.6
6 46 M PG NO 11 Ulcer in toes Healing 3.5 8.9 9.8
7 29 M PG NO 35 Ulcer in toes Healing 1.2 4.1 9.6
8 39 F BP (occlude) NO 31 Ulcer in toe Healing 0.3 5.9 11.3
9 45 M BP (occlude) NO 18 Ulcer in toe Ulcer
Improvement
0.9 4.9 10.1
10 39 F PG + LS YES 16 Ulcer in forefoot ICA 3.7 7.7 16.9
11 22 M PG + LS NO 13 Ulcer in toes Healing. Amp. 3
rd
toe
4.1 7.8 17.9
12.
a
49 M 2 BP
(permeable)
+P G
YES 12 Ulcer in toe Healing 2.3 6.9 12.3
12.
b
49 M PG YES 12 Ulcer in fingers Ulcer
Improvement
2.3 6.9 12.3
Abbreviations: BAFMD: brachial artery flow-mediated dilation test; ICA: Infracondylar amputation; Amp: Amputation; BP: Bypass; F: Female; M: Male; PG:
Prostaglandins; LS: Lumbar Sympathectomy; F/u: follow-up.
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During the follow-up, no new ischaemic lesions were
observed in the target extremities in all but one patient
whose ulcer had begun to heal and who, three months
after the end of bosentan treatment, had a relapse of an
ulcer on their toe. This relapse was treated with a new
four-month course of bosentan which managed to heal
the lesion. Only one patient required prolonging the
administration of bosentan beyond four months in order
to achieve total healing of the ulcers.
Overall, clinical improvement was observed in 12 of
the 13 extremities (92%) treated, while only one extre-
mity which presented lesions at the level of the forefoot
ultimately required major amputation below the knee.
Of the 12 extremities that improved, ten (77%) achieved
complete clinical therapeutic success (healing or com-
plete pain relief) [Table 1]. Moreover, a minor amputa-
tion of one toe was performed with conservation of the
extremity and healing of the ulcers of the other toes in
one patient. Two out of 13 extremities (15%) underwent
amputation (one major and one minor) after bosentan
treatment. Thus, an extremity conservation rate of 92%
was achieved.
All 10 of the lower extremities treated presented an
ABI lower than 0.6 before treatment. After the end of
bosentan treatment, the ABI increased by more than 0.1
in two patients. These differences were statistically non-
significant when compared with baseline values. None
of the three target upper extremities, which presented a
partial pressure below 50 mmHg at baseline, experi-
enced an increase in partial pressure above 10 mmHg
after bosentan treatment.
As assessed by digital arteriography with subtraction
or angio-MRI, after treatment with bosentan, evidence
of a qualitative improvement in distal flow was observed
in 10 out of the 12 patients, when compared with base-
line This result included an increase in the intensity of
the signal in the affected vessels at baseline angiography
as well as an increase in the number of visible collateral
vessels in two patients (Figure 1).
The BAFMD test was well tolerated in all patients.
Baseline endothelial function was reduced in all patients
(mean BAFMD = 1.8 ± 1.3%). After the end of bosentan
treatment, all patients experienced a significant improve-
ment in their values at this endpoint (mean BAFMD =
6.5 ± 1.3%), making this difference statistically signifi-
cant (p = 0.002). Three months after the end of treat-
ment with bosentan, the BAFMD values were also
higher than they were at the end of the treatment,
reaching a mean value of 12.7 ± 2.9% (p < 0.001).
Safety
No patient suffered serious adverse effects due to treat-
ment with bosentan leading to withdrawal of the treat-
ment. The repeated liver enzyme measurements
remained within the range of normality. Moreover,
Figure 1 Increased intensity of the signal in the affected vessels and visible collateral vessels.
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who presented haemoglobin values in the lower limit
and was treated with enteral iron. We did not find sta-
tistical differences in the levels of blood pressure in our
patients after the administration of Bosentan. The only
documented bosentan-associated adverse event was the
occurrence of transient oedema in the lower extremities
in 3 patients (25%), consistent with the vasodilatory
effect of the distal bed associated with bosentan use. No
new safety signals were observed.
Discussion
As TAO is associated with both distal ulcers in the
extremities and the possibility of amputation, it fre-
quently involves social problems and a worsening in the
quality of life of the affected patients [16]. Only a few
pharmacological and surgical options (of controversial
efficacy) are available to date [17]. New therapeutic
options with a higher efficacy than the current ones are
clearly needed in order to properly manage patients
affected by TAO.
Our study is a small pilot study and, as a result, it is
not possible to draw firm conclusions from it. On the
contrary, its objective should be to generate hypotheses
which firstly require further confirmation in larger pro-
spective studies, and secondly, a definitive assessment in
comparative randomised trials. In any case, the charac-
teristics of this disease, the low incidence and the lack
of effective treatments that improve the course of the
disease or correct the cause, contributes to serious ethi-
cal difficulties in carrying out this type of studies in this
particular disease. We consider special and important
the value of the results obtained in our study and the
immediate applicability in the clinical practice. This
study should be considered in this setting. However, our
results show that bosentan therapy was associated with
several clinical and endothelial function-related out-
comes in patients with TAO, which may be promising.
This report adds data to previous single reports [18,19]
on the efficacy of bosentan and the management of
patients with TAO.
Both clinical improvement and complete healing of
the ulcers were achieved in the majority of the target
extremities despite the documented failure to give up
smoking in the majority of the patients. Moreover, the
only major amputation was performed in a patient who
gave up smoking definitively. This result compares
favourably with a 19% major amputation rate in 69
patients who continued smoking, previously reported in
a series involving 110 patients with TAO [16]. The pros-
tacyclin analogue iloprost has shown modest efficacy in
randomised clinical trials. In a trial of intravenous ilo-
prost versus aspirin [20], healing of ulcers was higher in
the iloprost arm and was observed in 18 out of 52
patients receiving iloprost (35%). In another trial, an
oral formulation of iloprost was not better than placebo
with regard to this outcome [21]. In the aggregate, the
efficacy results shown by prostacyclin analogues when
used for the management of TAO are far from satisfac-
tory. On the contrary, in our study, 10 out of 12 ulcers
have improved (83%), of which eight have healed.
Although these results are from a small study and are
not comparable with those from randomised trials, they
seem to be promising.
G i v i n gu ps m o k i n g ,t h eo n l yt h e r a p e u t i cp r o c e d u r e
that has proven to be successful in TAO, was achieved
in only four out of 12 patients (33%). This unsatisfactory
rate is in accordance with previous reports which high-
light the fact that it was extremely difficult for patients
who are heavy smokers to give up smoking despite hav-
ing strongly been advised to do so, as well as having
received full information about the benefits of giving up
smoking, especially in terms of avoiding amputations
[22]. Patients reported their tobacco consumption and
no medical diagnostic test was used to confirm the
absolute cessation of smoking, which represents a lim-
itation of this clinical study.
The majority of our patients had been treated with
prostanoids, bosentan being the frontline pharmacologi-
cal regimen in only two patients. Moreover, four out of
the 13 target extremities had been surgically treated
(lumbar sympathectomy or by-pass procedures). Thus,
almost all patients included in this study should be con-
sidered refractory to previous therapeutic strategies.
Taken together, the data on previous treatments as well
as the high rate of smoking continuation reveal that the
patients in our study were difficult to manage, given
that they presented previous negative prognostic factors.
A possible explanation for the bosentan pharmacody-
namic effect on endothelial function is based on the
endothelial function impairment observed in patients
with peripheral arterial disease in general [11] and in
TAO patients in particular [23]. In addition, bosentan
has shown that it can improve endothelial function, at
least in patients with systemic sclerosis [24]. Thus, there
is a mechanistic background to explain our results on
endothelial function, which was indirectly measured in
our study by means of BAFMD. In fact, BAFMD results
clearly improved in every patient treated and also in the
overall mean value.
Moreover, an elevated serum ET-1 level has been
observed in patients with TAO, supporting a possible
mechanistic explanation of the clinical benefit of bosen-
tan in these patients [25]. Adverse events of bosentan
treatment were as expected. Notably, liver tolerance was
excellent and anaemia required iron supplementation in
only one patient. Compliance with the treatment was
also excellent (monitored by pill counts in every follow-
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treatment as a consequence of adverse events.
Conclusions
The hypothesis that bosentan treatment in TAO
patients results in an improvement of clinical, angio-
graphic and endothelial function outcomes is supported
by the results of this small pilot study. Bosentan should
be investigated further with regard to TAO patient man-
agement. New clinical trials with a control group should
be performed to confirm our results. In the meantime,
bosentan should be considered as a promising investiga-
tional agent for treating these patients.
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